Drug intelligence / Profile preview

sh-Polypeptide-9

Development stage
Unknown
Lead developer
Caregen
Modality
Peptides, Recombinant Proteins and Enzymes
Administration
Topical, Injection
01

Overview

sh-Polypeptide-9, also known as CG-VEGF or Vascular Endothelial Growth Factor Substitute Peptide, is a synthetic recombinant biomimetic peptide designed to replicate the biological activity of endogenous vascular endothelial growth factor (VEGF). Developed primarily by Caregen, this peptide acts as an agonist for VEGF receptors, particularly VEGFR-2, thereby stimulating angiogenesis, promoting microcirculation, and enhancing the delivery of nutrients to tissues such as hair follicles and skin cells. It is widely utilized in aesthetic medicine and dermatology, specifically in injectable hair fillers (e.g., Dr. CYJ Hair Filler) and topical treatments for androgenetic alopecia and skin rejuvenation. By activating the VEGF signaling pathway, it encourages the proliferation of endothelial cells and dermal papilla cells, supporting the growth phase of the hair cycle and improving tissue repair and vascularization.

Brand names
CG-VEGF
Other names
Vascular Endothelial Growth Factor Substitute PeptideVEGF-mimetic peptideRecombinant Human Vascular Endothelial Growth Factor Substitute Peptide
02

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)

Beyond the preview

Go deeper on sh-Polypeptide-9.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on sh-Polypeptide-9.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call